Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Adalimumab in Peripheral Spondyloarthritis
2009-014567-39Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of adalimumab in peripheral spondyloarthritis (pSpA) and spondyloarthritis (SpA), sponsored by AbbVie Inc. Primary endpoint: Primary clinical response endpoint. Started Dec 2009; status: completed.
02
Drugs
03
Conditions
peripheral spondyloarthritis (pSpA)spondyloarthritis (SpA)
Beyond the preview
Go deeper on 2009-014567-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014567-39.